Management of Residual Disease After First-line Chemotherapy in a Patient With a Nonseminomatous Germ Cell Tumor
ONCOLOGY · 2021
DOI: 10.46883/2021.25920932 ↗Kurz gefasst
Fallbericht in der Zeitschrift ONCOLOGY, 2021. Verfasst von Regina Barragán-Carrillo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hematology-Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Hematology-Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
- Radiology Department, Hospital Médica Sur, Mexico City, Mexico.
- Urology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
- Genitourinary Unit. Instituto Alexander Fleming. CABA, Buenos Aires, Argentina.
- Urology Department, Hospital Country 2000, Guadalajara, Mexico.
- University of Colorado Denver, School of Medicine, Aurora, CO.
Zitieren
APA
Barragán-Carrillo, R., Mateos-Corella, S., Ortiz-Hidalgo, C., Izquierdo-Echavarri, E., Castillejos-Molina, R., Angel, M., Barragan-Arteaga, I., Flaig, T., & Bourlon, M. T. (2021). Management of Residual Disease After First-line Chemotherapy in a Patient With a Nonseminomatous Germ Cell Tumor. ONCOLOGY. https://doi.org/10.46883/2021.25920932
Vancouver
Barragán-Carrillo R, Mateos-Corella S, Ortiz-Hidalgo C, Izquierdo-Echavarri E, Castillejos-Molina R, Angel M, et al. Management of Residual Disease After First-line Chemotherapy in a Patient With a Nonseminomatous Germ Cell Tumor. ONCOLOGY. 2021. doi:10.46883/2021.25920932
BibTeX
@article{BarragnCarrillo2021,
author = {Barragán-Carrillo, Regina and Mateos-Corella, Samantha and Ortiz-Hidalgo, Carlos and Izquierdo-Echavarri, Eva and Castillejos-Molina, Ricardo and Angel, Martín and Barragan-Arteaga, Ignacio and Flaig, Thomas and Bourlon, María},
title = {Management of Residual Disease After First-line Chemotherapy in a Patient With a Nonseminomatous Germ Cell Tumor},
journal = {ONCOLOGY},
year = {2021},
doi = {10.46883/2021.25920932}
}
EUVIMED